17:34 , May 4, 2018 |  BC Week In Review  |  Company News

DIAN, Roche, Foundation in Chinese genomic profiling deal

Foundation Medicine Inc. (NASDAQ:FMI), DIAN Diagnostics Group Co. Ltd. (SZSE:300244) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to integrate Foundation Medicine's suite of genomic profiling (CGP) tests into clinical patient care in China. The tests include FoundationOne,...
16:35 , Mar 9, 2018 |  BioCentury  |  Strategy

Accelerating Flatiron

Roche isn’t saying much about how it approached the decision to shell out $1.9 billion to acquire the 87% of Flatiron Health Inc. it didn’t already own. But it appears that Flatiron would have needed...
01:08 , Jul 30, 2015 |  BC Extra  |  Company News

Foundation Medicine lowers guidance

Foundation Medicine Inc. (NASDAQ:FMI) shed $3.80 (13%) to $25.50 in early after-hours trading on Wednesday after the precision medicine company lowered its 2015 revenue guidance to $85-$95 million from $105-$115 million. On a conference call,...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Company News

Foundation Medicine, Roche deal

Roche partnered with Foundation Medicine to develop diagnostics and will acquire 52.4-56.3% of Foundation through a $1 billion cash and stock deal expected to close next quarter. Roche will pay $780 million in cash and...
08:00 , Jan 19, 2015 |  BioCentury  |  Strategy

Accelerating the Foundation

The deal between Roche and Foundation Medicine Inc. gives Foundation the capital and commercial reach necessary to maintain its first-mover advantage in cancer genome profiling and could help the company attain its goal of making...
03:24 , Jan 13, 2015 |  BC Extra  |  Company News

Roche takes majority stake in Foundation Medicine

Foundation Medicine Inc. (NASDAQ:FMI) rose $22.81 (95%) to $46.74 on news that Roche (SIX:ROG; OTCQX:RHHBY) will acquire 52.4% to 56.3% of the company through a $1 billion cash and stock deal. Roche will pay $780...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

FoundationOne: Clinical trial started

Foundation Medicine said The Addario Lung Cancer Medical Institute (ALCMI) and Bonnie J. Addario Lung Cancer Foundation (ALCF) will use the company’s FoundationOne assay in the international Genomics of Young Lung Cancer study in about...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

FoundationOne regulatory update

Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass.   Product: FoundationOne   Business: Diagnostic   Foundation Medicine said it received final approval from the New York State Department of Health for 2 laboratory-developed tests for profiling genomic...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

FoundationOne Heme regulatory update

Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass.   Product: FoundationOne Heme   Business: Diagnostic   Foundation Medicine said it received final approval from the New York State Department of Health for 2 laboratory-developed tests for profiling...
23:44 , Apr 16, 2014 |  BC Extra  |  Financial News

Foundation Medicine withdraws follow-on

Pharmacogenetics company Foundation Medicine Inc. (NASDAQ:FMI) withdrew a proposed follow-on, citing market conditions. The company filed to raise $150 million in the offering last month, when its share price was $39.43. Goldman Sachs and JPMorgan...